- Home
- BETR vs BIOA Comparison
BETR vs BIOA Comparison
Compare BETR & BIOA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BETR | BIOA |
|---|---|---|
| Founded | 2014 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 480.9M | 443.9M |
| IPO Year | N/A | 2024 |
Fundamental Metrics
Financial Performance| Metric | BETR | BIOA |
|---|---|---|
| Price | $29.77 | $19.12 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 1 | 4 |
| Target Price | ★ $40.00 | $33.33 |
| AVG Volume (30 Days) | 481.3K | ★ 1.0M |
| Earning Date | 03-17-2026 | 03-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $145,545,000.00 | $5,917,000.00 |
| Revenue This Year | $53.90 | N/A |
| Revenue Next Year | $66.85 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 43.79 | N/A |
| 52 Week Low | $8.91 | $2.88 |
| 52 Week High | $94.06 | $24.00 |
Technical Indicators
Market Signals| Indicator | BETR | BIOA |
|---|---|---|
| Relative Strength Index (RSI) | 37.71 | 58.91 |
| Support Level | $28.08 | $18.20 |
| Resistance Level | $36.30 | $19.88 |
| Average True Range (ATR) | 3.16 | 1.91 |
| MACD | -0.01 | -0.28 |
| Stochastic Oscillator | 13.84 | 46.12 |
Price Performance
Historical ComparisonAbout BETR Better Home & Finance Holding Company
Better Home & Finance Holding Co is a digital-first homeownership company whose services include mortgage, real estate, title, and homeowners insurance. The company has combined technology innovation and fresh thinking with a deep customer focus with the goal of revolutionizing the homeownership industry.
About BIOA BioAge Labs Inc.
Bioage Labs Inc is a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases, such as obesity, by targeting the biology of human aging. Its focus is metabolic disease, one of the greatest healthcare challenges. The pipeline Products of the company are NLRP3 inhibitors, APJ against, and others.